www.foxnews.com
The FDA has greenlit Paradromics’ first human clinical trial for its groundbreaking brain-computer interface (BCI). This marks a significant step towards restoring speech for individuals paralyzed and unable to communicate verbally. Paradromics’ technology aims to decode neural signals associated with speech intent and translate them into understandable language. The trial will assess the safety and efficacy of the BCI in patients with paralysis, offering hope for a future where these individuals can regain the ability to communicate effectively and improve their quality of life. This represents a major advancement in neural technology and its potential to address debilitating conditions.
